Возможности адекватного выбора различных препаратов аспарагиназы

1. Kidd J.G. Regression of transplanted lymphomas induced in vivo by means of normal guinea-pig serum: I. Course of transplanted cancer of various kinds in mice and rats given guinea-pig serum , horse serum or rabbit serum. J Exp Med 1953;98:568—82.

2. Sobin L.H., Kidd J.G. The incorporation of l-asparagin-14C by lymphoma 6C3HED cells: its inhibition by guinea-pig serum. Cancer Res 1966;26(2):208—11.

3. Sobin L.H., Kidd J.G. Alterations in protein and nucleic acid metabolism of lymphoma 6C3HED-og cellas in mice given guinea-pig serum. J Exp Med 1966;123(1):55—74.

4. Broome J.D. Antilymphoma activity of L-asparaginase in vivo: clearance rate of enzyme preparations from guinea-pig serum and yeast in relation of their effects on tumor growth. J Natl Acad Sci U S A 1965;35:967—74.

5. Yellin T.O., Wriston J.C. Purification and properties of guinea-pig serum asparaginase. Biochemistry 1966;5:1605—12.

6. Mashburn L.T., Wriston J.C. Tumor inhibitory effect of L-asparaginase from Escherichia coli. Arch Biochem Biophys 1964;105:451—2.

7. Asselin B.L., Whitin J.C., Coppola D.J. et al. Compartive pharmacokinetic studies of three aspsraginase preparation. J Clin Oncol 1993;11:1780—6.

8. Khan A., Hill J.M. Atopic hypersensitivity to L-asparaginase: resistance to immunosuppression. Int Arch Allergy Appl Immunol 1971;40(3):463—569.

9. Ertel I.J., Nesbit M.E., Hammond D. et al. Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphoblastic leukemia: a report from Childrens Cancer Study Group. Cancer Res 1979;39(10):3893—6.

10. Albertsen B.K., Schroder H., Ingerslev J. et al. Comparison of intramuscular therapy with Erwinia asparaginase and asparag-ibase Medac: pharmacokinetics pharmacodynamics, formation of antibodies and influence on coagulation system. Br J Hematol 2001;96(5):983—90.

11. Albertsen B.K., Jacibsen P., Schroder H. et al. Pharmacokinetics of Erwinia asparaginase after intravenous and intramuscular administration. Cancer Chemither Pharmacol 2001;48(1):77—82.

12. Albertsen B.K., Schroder H., Jacibsen P. et al. Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries. Br J Clin Pharmaco 2001;52:433—7.

13. Sallan S.E., Hitchcock-Bryan S. Gelberg R. et al. Influence of intensive asparaginase in treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res 1983;43(11):5601—7.

14. Abshire T.C., Pollock B.H., Billet A.L. et al. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia leukemia: a Pediatric Oncology Group Study. Blood 2000;96(5):1709—15.

15. Hawkims D.S., Park J.R., Thomson B.G. et al. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase for children with relapsed acute lymphoblastic leukemia. Clin Cancer Res 2004;10(16):5335—41.

16. Holcenger J.S., Teller D.C. Physical properties of antitumor glutaminase-asparaginase from Pseudomonas 7A. J Biol Chem 1976;251(17):5375—80.

17. Avramis V.I., Sencer S., Periclou A.P. et al. Randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children’s Cancer Study Group. Blood 2002;99(6):1986—94.

18. Panosyan E.H., Seibel N.L., Gaynon P.S. et al. Asparaginase antibody and asparaginase activity in childhood in higher risk acute lymphoblastic leukemia: Children’s Cancer Group Study CCG-1961. J Pediatr Hematol Oncol 2004;26(4):217—26.

19. Asselin B.L., Whitin J.C., Coppola D.J. et al. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993;11(9):1780—6.

20. Boos J., Werber G., Ahlke E. et al. Monitoring of asparaginase activity and asparagine levels in children with different asparaginase preparations. Eur J Cancer 1996;32A(9):544—50.

21. Ahlke E., Nowak-Gottl U., Schultze-Westhoff P. et al. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukemia. Br J Hematol 1997;96:675-81.

22. Muller H.J., Loning L., Horn A. et al. Pegilated asparaginase (OncasparTM) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br J Hematol 2000;110:379-84.

23. Vieira Pinherio J.P., Ahlke E., Nowak-Gottl U. et al. Pharmacokinetic of dose adjustment of Erwinia asparaginase in protocol II of the pediatric ALL/NHL-BFM treatment protocols. Br J Hematol 1999;104:313-20.

24. Vieira Pinherio J.P., Muller H.J., Schwabe D. et al. Drug monitoring of low dose PEG-asparaginase (Oncaspar™) in children with relapsed acute lymphoblastic leukemia (ALL). Br J Hematol 2001;113:115-9.

25. Muller H.J., Beier R., da Palma J.C. et al. PI^G-asparaginase (Oncaspar™) 2,500 U/m BSA in re-induction and relapse treatment of the ALL/NHL-BFM protocols. Cancer Chemother Pharmacol 2002;49:149-54.

26. Gaynon P.S., Harris R.E., Stram S.O. et al. Asparagine (ASN) depletion and treatment response in chikdhood acute lymphoblastic leukemia (ALL) after an early marrow relapse: a Children’s Cancer Group trial (CCG-1941) [abstract]. Blood 1999;94(10 Suppl 1):628a.

27. Panosyan E., Avramis I.A., Seibel N.L. et al. Glutamine (Gln) deamonation by asparaginases (ASNases) in children with high risk acute lymphoblastic leukemia (HR ALL), (CCG-1961 study) [abstract]. Blood 2002;100:759A.

28. Avramis V.I., Panosyan E.H. Pharmacokinetic/Pharmacodynamic relations of asparaginase formulations the past, the present and recommendations for the future. Clin Pharmacokokinet 2005;44(4):367-93.

29. Vieira Pinherio J.P., Wenner K., Escherich G. et al. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 U/m PEG asparaginase in children with ALL treated according to protocol COALL-06-97. Pediatr Blood Cancer 2006;46:18-25.

30. Rizzari C., Zucchetti M., Conter V. et al. L-Asparagine depletion and L-asparag-inase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C or E. coli L-asparaginase as the first exposure. Ann Oncol 2000;11(2):189-93.

31. Avramis V.I., Senser S., Periclou A.P. et al. A randomized comparison of native Escherichia coli aspsraginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard risk acute lymphoblastic leukemia: a Children’s Cancer Group study. Blood 2002;99:1986-94.

32. Appel I.M., Pinheiro JPV., den Boer M.K. et al. Lack of asparagines depletion in the ceredrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL. Leukemia 2003;17:2254-6.